-
Global Biotechnology & Pharmaceutical Markets2 months agoChina’s clinical trial boom under scrutiny after 3 deaths come to light
Two House Republicans are asking the FDA to increase oversight of China-generated clinical data after three trial deaths are reported.
-
Global Biotechnology & Pharmaceutical Markets2 months agoK2 Therapeutics: Spreading bets across range of Asia-sourced assets
BIOCENTURY | EMERGING COMPANY PROFILEK2 THERAPEUTICS: SPREADING BETS ACROSS RANGE OF ASIA-SOURCED ASSETSFormer Legend CEO Ying Huang looks to $250M series A while aiming to replicate...
-
Global Biotechnology & Pharmaceutical Markets2 months agoSTAT+: 5 burning questions on Trump’s latest deals with drugmakers
Here are some of the key questions about the agreements the Trump administration has reached with drugmakers on pricing.
-
Global Biotechnology & Pharmaceutical Markets2 months agoSTAT+: Novartis gets multiple sclerosis win with BTK inhibitor
More Trump drug pricing deals, GSK speeds up development of mRNA flu vaccine, and other biotech news
-
Global Biotechnology & Pharmaceutical Markets2 months agoSTAT+: Trump strikes nine more deals with drugmakers to lower prices
President Trump on Monday announced the next round of pricing deals with drugmakers, with nine new companies making such agreements.
Helixgate Featured18 hours ago
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Capital, M&A & Industry Strategy21 hours ago
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
AI, Machine Learning & Computational Biology21 hours ago
100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Uncategorized7 months ago
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Uncategorized6 months ago
